Nanalysis Sci Stock Price, News & Analysis

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has announced the release of new automation software aimed at simplifying NMR spectroscopy for industrial applications. The qNMR module is designed to automate routine qNMR assays, making it easier for technicians to collect data without requiring expertise in NMR spectroscopy.

The software is compatible with both the company's 100 MHz and 60 MHz products, and works with autosamplers for increased throughput. This development addresses a key challenge in implementing NMR technology in quality control and quality assurance environments, where traditional NMR instrumentation has been impractical.

The company has implemented a four-pronged strategy to expand its benchtop NMR platforms in industrial QA/QC:

• Identifying and validating methods with strong ROI
• Ensuring data integrity requirements
• Exploring regulation compliance
• Reducing expertise barriers

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has launched its next-generation 60 MHz Benchtop NMR spectrometer at the Pittcon Conference and Expo in Boston. The new Nanalysis-60 represents a significant upgrade from the previous model, featuring:

• Enhanced power and sensitivity for analyzing small compound amounts
• Improved accuracy and resolution for better compound quantification
• Advanced automation with autosampler and flow cell capabilities
• Optional features including Pulsed-Field Gradients for 2D NMR analysis

The new model, priced between the legacy 60 MHz and 100 MHz versions, targets pharmaceutical, food, chemical, security, advanced materials, mining, and academic sectors. The company will continue offering its original 60 MHz instrument for price-sensitive customers while positioning this new version for industry customers requiring advanced capabilities.

Nanalysis Scientific Corp (OTCQX: NSCIF) has reported strong preliminary Q4 2024 results, with revenue of at least $11 million and record quarterly adjusted EBITDA exceeding $1 million. This represents growth of at least $1.2MM in revenue and $1.8MM in adjusted EBITDA compared to Q4 2023.

The company achieved significant milestones including positive operating and free cash flow in 2024, record sales of 15 100MHz Benchtop NMR units in Q4, and approximately $26 million in security services revenue for 2024. The security services business improved from negative gross margins at the start of 2024 to positive double-digit margins by year-end.

Notable achievements include a co-published study with USP demonstrating Benchtop NMR efficacy for pharmaceutical quality control and two new US patents for NMR magnet and software platform technology. While achieving positive EBITDA and cash flow, after-tax Net Income remained negative for 2024.

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) and the United States Pharmacopeia (USP) have published a study confirming the effectiveness of benchtop NMR for quality control of active pharmaceutical ingredients. The study highlights benchtop NMR's potential in the multi-billion-dollar pharmaceutical quality control market.

The technology offers several advantages including faster measurements, reduced solvent consumption, simple sample preparation, calibration-free operation, and non-destructive testing. USP's automated analysis method, USP-ID, reduces barriers to entry for benchtop NMR in pharma/biotech QC applications.

The company plans to submit multiple benchtop NMR methods to USP for acceptance, targeting expansion into global pharmacopeia jurisdictions including Europe and Japan.

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) reported strong Q3 2024 results with 50% year-over-year revenue growth to $10.6 million. The company achieved positive EBITDA of $264K, compared to a loss of $1,354K in Q3 2023. Product sales gross margin improved to 52% from 41%, while security services margin rose to 15% from -3%. Net loss decreased to $1,644K from $6,287K in the previous year. The company saw strength in both core segments: product sales and security services, with the latter showing consistent revenue growth following complete airport service transition in Q1 2024.

Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has scheduled its Third Quarter 2024 earnings conference call for Thursday, November 21st, 2024, at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will discuss results for the quarter ended September 30, 2024. Investors can join via phone (1-888-510-2154 or 289-819-1450 internationally) or through a webcast. A separate European Q&A session is scheduled for Friday, November 22nd at 8:30 AM ET. The webcast will be archived for 90 days, and a seven-day telephonic playback will be available.

Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines and MRI technology, announces its participation in the 17th annual LD Micro Main Event. CEO Sean Krakiwsky will present on Wednesday, October 30th at 3:00 PM PT/6:00 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles.

The event, running from October 28th to 30th, will feature approximately 150 companies presenting in half-hour increments and attending private investor meetings. Registration begins at 3:00 PM PT on the 28th, followed by keynotes and a happy hour. Presentations will run from 8:00 AM to 5:00 PM PT on the 29th and 30th.

Interested parties can register to watch the virtual presentation through the provided link to the LD Micro Main Event XVII 2024 on Sequire Events.

Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF), a leader in portable NMR machines and MRI technology for industrial and research applications, has announced its participation in the upcoming Cantech Letter Investment Conference on October 9, 2024 in Toronto, Ontario. Sean Krakiwsky, the company's CEO, will deliver an investor presentation and engage in one-on-one meetings with investors during the event.

The conference will take place at the Arcadian Loft, 8th floor, 401 Bay Street, Toronto, ON. Interested parties can register by contacting tara@cantechletter.com. Krakiwsky expressed enthusiasm about the opportunity, stating that the conference provides an excellent platform to strengthen connections within the capital markets, enhance visibility, showcase achievements, and increase the company's profile among investor communities.

Nanalysis Scientific Corp. (OTCQX: NSCIF) has reported significant growth in Q2 2024 with a 65% YoY revenue increase to $11.5M, driven by strong sales in benchtop NMR and security services, along with substantial medical imaging hardware sales. The company achieved a positive EBITDA of $414K compared to a loss of $2.4M in Q2 2023. Product sales totaled $5.4M, while service revenue soared to $5.3M, marking a 144% increase. Gross margin on product sales rose to 50%, and security services saw a 46% improvement. Significant cost reductions and efficiency improvements contributed to a net loss reduction to $2M from $4.1M. CEO Sean Krakiwsky expressed optimism for H2 2024, citing historical seasonal strength and ongoing margin improvements.